Ryan & Maniskas, LLP Announces Investigation of Inhibitex, Inc.
10 Enero 2012 - 9:37AM
Business Wire
Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/inhx) is
investigating potential claims against the board of directors of
Inhibitex, Inc. ("Inhibitex" or the "Company") (NASDAQ: INHX)
concerning possible breaches of fiduciary duty and other violations
of law related to the Company’s efforts to sell Inhibitex to
Bristol-Myers Squibb Co. in a transaction valued at approximately
$2.5 billion.
Our investigation concerns possible breaches of fiduciary duty
and other violations of law related to the approval of the
transaction by Company’s board of directors; in particular, whether
the Company undertook a fair process to obtain fair consideration
for all shareholders of Inhibitex. For more information regarding
our investigation, please contact Ryan & Maniskas, LLP (Richard
A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at
rmaniskas@rmclasslaw.com or visit:
www.rmclasslaw.com/cases/inhx.
Under the terms of the definitive agreement, Inhibitex
shareholders will receive $26 per share of Inhibitex stock they
own.
If you own shares of Inhibitex and would like to learn more
about these claims or if you wish to discuss these matters and have
any questions concerning this announcement or your rights, contact
Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign
up online, visit: www.rmclasslaw.com/cases/inhx. You may also email
Mr. Maniskas at rmaniskas@rmclasslaw.com. For more information
about class action cases in general, please visit our website:
www.rmclasslaw.com.
Ryan & Maniskas, LLP is a national shareholder litigation
firm. Ryan & Maniskas, LLP is devoted to protecting the
interests of individual and institutional investors in shareholder
actions in state and federal courts nationwide.
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Inhibitex, Inc. (MM) (NASDAQ): 0 recent articles
Más de Ryan & Maniskas, LLP Artículos de Noticias